Pacira Pharmaceuticals (PCRX) Now Covered by Seaport Global Securities

Equities research analysts at Seaport Global Securities assumed coverage on shares of Pacira Pharmaceuticals (NASDAQ:PCRX) in a research report issued on Friday. The firm set a “buy” rating on the stock.

A number of other equities analysts have also recently commented on PCRX. Mizuho restated a “buy” rating and set a $53.00 target price on shares of Pacira Pharmaceuticals in a report on Monday, September 25th. Needham & Company LLC restated a “buy” rating on shares of Pacira Pharmaceuticals in a report on Tuesday, September 26th. Goldman Sachs Group started coverage on Pacira Pharmaceuticals in a report on Thursday, September 28th. They set a “neutral” rating and a $41.00 target price for the company. Canaccord Genuity restated a “buy” rating and set a $44.00 target price (down from $48.00) on shares of Pacira Pharmaceuticals in a report on Sunday, October 1st. Finally, Zacks Investment Research raised Pacira Pharmaceuticals from a “hold” rating to a “buy” rating and set a $42.00 price target on the stock in a research report on Tuesday, October 3rd. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $49.00.

Pacira Pharmaceuticals (NASDAQ PCRX) opened at $39.10 on Friday. The firm has a market capitalization of $1,634.97, a price-to-earnings ratio of -29.85 and a beta of 2.20. The company has a current ratio of 6.99, a quick ratio of 6.24 and a debt-to-equity ratio of 1.03. Pacira Pharmaceuticals has a twelve month low of $29.81 and a twelve month high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Wednesday, November 8th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The company had revenue of $67.30 million during the quarter, compared to analysts’ expectations of $68.99 million. During the same period last year, the business posted $0.20 EPS. Pacira Pharmaceuticals’s revenue for the quarter was down 1.6% on a year-over-year basis. research analysts predict that Pacira Pharmaceuticals will post -0.85 earnings per share for the current year.

In related news, CEO David M. Stack sold 28,885 shares of the firm’s stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $40.19, for a total transaction of $1,160,888.15. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP James B. Jones sold 850 shares of the firm’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $41.11, for a total value of $34,943.50. The disclosure for this sale can be found here. Insiders have sold a total of 98,960 shares of company stock worth $3,868,341 in the last 90 days. 6.60% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in PCRX. HealthCor Management L.P. grew its stake in Pacira Pharmaceuticals by 63.1% during the 2nd quarter. HealthCor Management L.P. now owns 1,793,799 shares of the company’s stock worth $85,564,000 after buying an additional 693,799 shares during the last quarter. Mesirow Financial Investment Management Equity Management purchased a new position in shares of Pacira Pharmaceuticals in the 3rd quarter valued at approximately $14,671,000. Stonepine Capital Management LLC purchased a new position in shares of Pacira Pharmaceuticals in the 3rd quarter valued at approximately $14,089,000. Epoch Investment Partners Inc. grew its stake in shares of Pacira Pharmaceuticals by 195.7% in the 3rd quarter. Epoch Investment Partners Inc. now owns 535,999 shares of the company’s stock valued at $20,127,000 after purchasing an additional 354,728 shares during the last quarter. Finally, BlackRock Inc. grew its stake in shares of Pacira Pharmaceuticals by 9.2% in the 2nd quarter. BlackRock Inc. now owns 3,478,281 shares of the company’s stock valued at $165,914,000 after purchasing an additional 294,494 shares during the last quarter.

TRADEMARK VIOLATION NOTICE: “Pacira Pharmaceuticals (PCRX) Now Covered by Seaport Global Securities” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/19/pacira-pharmaceuticals-pcrx-now-covered-by-seaport-global-securities.html.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply